1. Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations. (3rd June 2017) Authors: Armstrong, A.; Bui, C.; Fitch, K.; Sawhney, T. Goss; Brown, B.; Flanders, S.; Balk, M.; Deangelis, J.; Chambers, J. Journal: Current medical research and opinion Issue: Volume 33:Number 6(2017) Page Start: 1133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗